Independent, evidence-based peptide science intelligence. Our editorial team combines expertise in peptide chemistry, molecular pharmacology, and biotech industry analysis.
Information date: 8 September 2026 — FDA exposure-response guidance describes relationships among dose, concentration, response and time as central to drug-development decisions; a downstream biomarker without exposure c
Information date: 8 September 2026 — FDA explains that cosmetic status and claims depend on intended use: claims to treat disease or affect the structure or function of the body can place a product within drug requiremen
Information date: 8 September 2026 — The U.S. National Institute on Aging studies cellular senescence as a biological process in which cells stop dividing and can influence tissues, but the presence or change of a senesc
Information date: 7 September 2026 — FDA records show navepegritide, marketed as Yuviwel, received marketing approval on 27 February 2026 to increase linear growth in pediatric patients aged two years and older with acho
Information date: 7 September 2026 — FDA’s July 2026 Pharmacy Compounding Advisory Committee materials included a dedicated briefing document for BPC-157-related bulk drug substances as part of a public review of nominat
Information date: 7 September 2026 — ICH Q14, adopted by FDA, frames analytical procedure development around an intended purpose, relevant performance characteristics, scientific understanding and lifecycle control rathe
Information date: 7 September 2026 — FDA bioanalytical guidance identifies endogenous compounds as a special validation challenge when an assay cannot distinguish the administered therapeutic from the endogenous counterp
